Media

Talks and interviews

Thumbnails and outbound links first. YouTube can be loaded as a privacy-enhanced embed on request. We do not assume VJHemOnc may be embedded.

Amin Turki speaking in the University of Duisburg-Essen Medical Faculty video, identified on screen as Clinic for Bone Marrow Transplantation and Institute for Cell Therapeutic Research.

UDE Medical Faculty · 2020

Dr. Dr. Amin Turki

Faculty video in which Amin Turki introduces his work at the Clinic for Bone Marrow Transplantation and the Institute for Cell Therapeutic Research. Published by the University of Duisburg-Essen Medical Faculty for the UMEA Clinician Scientist Academy (2020).

Watch →

HARMONY Alliance

HARMONY Alliance expert interview: Amin Turki, University of Essen

HARMONY Alliance expert interview with Amin Turki, University of Essen. Load the privacy-enhanced YouTube embed only on request; do not autoplay.

Watch →

Still from the VJHemOnc interview of Amin Turki on AI and digital innovation in transplant care.

SOHO 2025

How AI and digital innovation are transforming transplant care

Interview on AI and digital transformation in bone marrow transplantation, including data integration, digital monitoring, and individualized care.

Watch →

Still from the VJHemOnc interview of Amin Turki on real-time AI decision support in transplant care.

SOHO 2025

Opportunities and challenges for real-time AI decision support in transplant care

Discussion of decision-support systems, monitoring, and risk prediction after allogeneic transplantation, including validation and regulatory challenges.

Watch →

onkowissen.AUDIO · 2026

AML im Fokus, with Felicitas Thol and Amin Turki

Five-episode German-language series with Felicitas Thol and Amin Turki, hosted by Friedrich Overkamp. The episodes cover AML diagnostics and first treatment planning, therapy for fit and unfit patients, supportive care, measurable residual disease, and clinical studies including AI. Listen on the series page.

Listen →

Press and other records

Still from the VJHemOnc interview of Amin Turki on MRD as a surrogate endpoint in AML.

ASH 2025

Validation of MRD as a surrogate endpoint in AML: ongoing research & updates from HARMONY Alliance

Turki discusses HARMONY Alliance work on measurable residual disease as a risk factor and possible surrogate endpoint, and distinguishes a colleague's MRD-surrogacy analysis from his genetics abstract. Do not imply first authorship of the MRD surrogacy study.

Watch →